Neurotrack

Profile Information

Conference
DEMO Fall 2012
Market Segment
Health
Funding Amount
Product Description
Neurotrack has developed a technology that can diagnose Alzheimer's disease three to four years before symptoms appear. It is a non-invasive, visual-cognitive computer-based test.
Funding Round
Seed
Funding Details
Neurotrack has received $50,000 in state grants from the Georgia Research Alliance for early commercialization efforts, and Emory University received approximately $2.3 million in NIH and Woodruff Foundation funds to support the scientific research.
Competitors
There are no competitors on the market that have developed a non-invasive predictive test.
Market Opportunity
Alzheimer’s is an epidemic, with 30M+ people worldwide who suffer from Alzheimer’s today, and those numbers are expected to increase exponentially. Critical to developing preventive drugs is the ability to diagnose Alzheimer's earlier and better test drugs in development. Neurotrack makes this possible.

Company Contact

URL
http://www.neurotrack.com
Facebook
Twitter
NA
LinkedIn
Contact
elli@neurotrack.com
Company Address
4200 Grove Ave., Richmond, VA 23221
Primary Phone
404-402-9863
Officer One
Elli Kaplan - Chairman, Board of Directors
Officer Two
-
Officer Three
-
Officer Four
-
Back to DEMO home